Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indiplon + sertraline is a combination of two small-molecule drugs: **indiplon**, a nonbenzodiazepine hypnotic agent that is a selective GABA\(_A\) receptor agonist, and **sertraline**, a selective serotonin reuptake inhibitor (SSRI) primarily used as an antidepressant. Indiplon was investigated for the treatment of insomnia due to its high affinity for the GABA\(_A\) α1 receptor subunit, producing sedative effects with minimal evidence of tolerance or withdrawal[4][6]. Sertraline is widely used as an SSRI for major depressive disorder, various anxiety disorders, and other conditions. The combination of indiplon and sertraline has been specifically investigated in the context of insomnia co-occurring with depressive symptoms[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on indiplon + sertraline.